Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Coronary Artery Disease
Interventions: Adenosine SPECT myocardial perfusion imaging, Combined adenosine / exercise SPECT myocardial perfusion imaging; Procedure
Lead sponsor: Midwest Heart Foundation; Other
Eligibility: 60 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 20
States / cities: Tucson, Arizona • Roseville, California • Sacramento, California + 16 more

Conditions: Central Nervous System Lymphoma
Interventions: Resting State fMRI (rsfMRI), Auditory Attention and Executive Functions Test, Memory Test, Motor Speed Test, Self Reported Quality of Life Questionnaire; Diagnostic Test · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Injuries, Anterior Cruciate Ligament Injuries, Ankle Injuries, Lower Extremity Injuries
Interventions: neuromuscular warm-up; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 14 Years to 80 Years
Enrollment: 1,653 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Diabetes Mellitus, Glucose, High Blood, Glucose, Low Blood
Interventions: Dexcom Generation 6 CGM (Dexcom Gen6) device; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Chronic Pain
Interventions: Ultra-high pulse width stimulation, Traditional pulse width stimulation; Device
Lead sponsor: Nuvectra; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Tucson, Arizona • Newport Beach, California • Santa Rosa, California + 7 more

Conditions: Breast Cancer
Interventions: 800 IU Vitamin D Supplement, 50,000 IU Vitamin D supplement; Drug
Lead sponsor: Mothaffar Rimawi; Other
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: Asymptomatic Hypertension
Interventions: Community Health Worker engagement; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Fighting Behavior, Aggression
Interventions: Mentoring and violence prevention curriculum with parental monitoring; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 9 Years to 15 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Esophageal Cancer, Esophageal Neoplasms
Interventions: Prehabilitation Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Troponin
Interventions: Not listed
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cervical Cancer, Precancerous Condition
Interventions: imiquimod, Ablative or excisional therapy; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma, Very High Risk Prostate Carcinoma
Interventions: 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy, Prostate Tissue Collection, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT), Blood Sample Collection; Drug · Procedure
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions: Artesunate, Placebo; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: liposomal cytarabine-daunorubicin CPX-351; Drug
Lead sponsor: Rondeep Brar; Other
Eligibility: 60 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, triacetyluridine; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Burbank, California • Duarte, California + 22 more

Conditions: Smoking Cessation
Interventions: Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention, E-Referral to the Tobacco Quitline; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: High Risk Pregnancy
Interventions: Not listed
Lead sponsor: Verinata Health, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Baldwin Park, California • Los Angeles, California • Panorama City, California + 1 more

Conditions: Sarcoma, Neuroblastoma, Wilm's Tumor
Interventions: Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT); Biological · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Up to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide, Pirtobrutinib; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • California City, California • Duarte, California + 18 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more

Conditions: Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: axitinib, therapeutic conventional surgery, enzyme-linked immunosorbent assay, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sarcoma
Interventions: graft versus host disease prophylaxis/therapy, busulfan, melphalan, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Both Exercise and Adenosine Stress Testing

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

Effect of Neuromuscular Warm-up on Injuries in Female Athletes

Continuous Glucose Monitoring of Hospitalized Patients With Diabetes

Algovita Spinal Cord Stimulation System Hi-Fi Study

High Dose Vitamin D vs Standard Dose Vitamin D Study

Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations

Community-Based Violence Prevention for High-Risk Youth

Esophageal Cancer Multimodal Prehabilitation Study

Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Tobacco Education and Lung Health Study (TEAL)

Investigation of the Impact of Noninvasive Prenatal Testing for Fetal Aneuploidy on Utilization of Prenatal Diagnostic Procedures and Pregnant Women's Views

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors